Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial
Kristeleit, Rebecca,
Lisyanskaya, Alla,
Fedenko, Alexander,
Dvorkin, Mikhail,
de Melo, Andreia Cristina,
Shparyk, Yaroslav,
Rakhmatullina, Irina,
Bondarenko, Igor,
Colombo, Nicoletta,
Svintsitskiy, Valentyn,
Biela, Luciano,
Nechaeva, Marina,
Lorusso, Domenica,
Scambia, Giovanni,
Cibula, David,
Póka, Róbert,
Oaknin, Ana,
Safra, Tamar,
Mackowiak-Matejczyk, Beata,
Ma, Ling,
Thomas, Daleen,
Lin, Kevin K,
McLachlan, Karen,
Goble, Sandra,
Oza, Amit M
Связанные документы (рекомендация CORE)
